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Impacts 14 
 Many countries require demonstration of an adequate level of anti-rabies antibodies in the 15 
blood (i.e., rabies titre of 0.5 IU/ml) to permit entry of dogs traveling internationally. 16 
 We analysed rabies titres of dogs seeking travel certification in Israel to assess 17 
demographic and vaccine history factors associated with not having an adequate rabies 18 
virus neutralizing antibody (RVNA) titre for travel certification. 19 
 Only having received one previous rabies vaccination and a longer time since the last 20 
vaccination was received were associated with not achieving an adequate RVNA titre for 21 
travel certification. 22 
 These findings reiterate the importance of the first booster vaccination for ensuring dog 23 
populations are protected against rabies. 24 
  25 
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Summary 26 
Rabies is endemic in wildlife or domestic carnivore populations globally. Infection of 27 
domestic dogs is of particular concern in many areas. In regions where domestic animals are 28 
at risk of exposure to rabies virus, dogs should be routinely vaccinated against rabies to 29 
protect both pet and human populations. Many countries require demonstration of an 30 
adequate level of serum rabies neutralizing antibodies to permit entry of dogs during 31 
international travel. We analysed rabies titres of dogs seeking travel certification in Israel to 32 
assess demographic and vaccine history factors associated with antibody titres below the 33 
acceptable threshold for travel certification. Having received only one previous rabies 34 
vaccination and a longer duration since the most recent vaccination was received were 35 
primary risk factors for not achieving an adequate RVNA titre for travel certification. These 36 
risk factors had stronger effects in younger animals, but were consistent for dogs of all ages. 37 
In particular, these findings reiterate the importance of administering at least two rabies 38 
vaccinations (the primo vaccination and subsequent booster) to ensure population-level 39 
protection against rabies in dogs globally. 40 
Key words: dogs, global travel, immunity, Israel, prevention, rabies, serology, vaccination 41 
Introduction 42 
Rabies is endemic in wildlife and domestic carnivore populations globally. In regions where 43 
domestic animals are at risk of rabies virus exposure, dogs should be routinely vaccinated 44 
against rabies to protect both pet and human populations from this nearly invariably fatal 45 
infection (WHO, 2015). In many countries rabies vaccination protocols are legally 46 
prescribed. Proof of rabies vaccination is typically required as a condition for international 47 
pet travel, both due to the risk of rabies virus exposure in endemic destinations and the risk of 48 
rabies virus introduction to rabies-free areas by unimmunized animals during travel 49 
(reviewed in Lankau et al., 2014). Countries vary in their dog entry regulations, which may 50 
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include a combination of age and identification method (e.g., microchipping) requirements, 51 
documentation of having received rabies vaccine a sufficient duration prior to travel to mount 52 
an immune response (i.e., proof of vaccination), serologic demonstration of immunity prior to 53 
travel, or a quarantine period before or after arrival (examples of different country 54 
requirements may be located at USDA, 2015). 55 
During the early 1990s, many countries converted from a strict quarantine 56 
requirement for domestic dog entry to requiring serological evidence of immunity (Cliquet et 57 
al., 2003). These changes were driven by both increasing interest in free-circulation of people 58 
and animals among countries and improved scientific understanding of the relationship 59 
between rabies antibody titre levels in dogs and cats and resistance to infection upon 60 
exposure (Aubert 1992, WHO 1992, Cliquet et al., 2003). In challenge experiments, a rabies 61 
virus neutralizing antibody (RVNA) titre of ≥0.5 international units (IU)/ml correlated best 62 
with protection from rabies virus infection on exposure (Aubert, 1992). The World Health 63 
Organization (WHO) designated RVNA titres of ≥ 0.5 IU/ml in an actively immunized dog 64 
>16 weeks of age as the standard for certifying protection against rabies infection (WHO, 65 
1992). Since 1993, the World Organization for Animal Health (OIE) has recommended 66 
requiring serologic evidence of immunity by quantification of RVNA whenever dogs or cats 67 
are imported from countries with endemic rabies virus circulation to areas that are considered 68 
rabies free (OIE, 1996). Many countries require demonstration of an adequate RVNA titre 69 
(≥0.5 IU/ml) for international movement of pets (in the European Union for example: EU, 70 
2003). Dogs with lower titres or even without detectable antibodies have survived virulent 71 
rabies challenge (Sikes et al., 1971; Brown et al., 1973; Barth and Jaeger, 1977; Ganiere et 72 
al., 1989; Aubert, 1992). 73 
In Israel, rabies is a notifiable disease according to the Animal Disease Ordinance 74 
(New Version) of 1985 and the Rabies Ordinance of 1934 (FAO, 2001; Israel Ministry of 75 
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Agriculture and Rural Development, 1934). Since 1956, domestic dogs in Israel must be 76 
vaccinated against rabies by law, first at three months old and then annually (Israel Ministry 77 
of Agriculture and Rural Development, 2015). Legally mandated vaccination of dogs 78 
substantially shifted the dominant rabies reservoir. While dogs were the most commonly 79 
affected through the mid-1950s (Nobel & Neumann, 1962; Yakobson et al., 2004), red foxes 80 
(Vulpes vulpes) and to a lesser extent golden jackals (Canis aureus) became the primary 81 
rabies reservoirs after 1956. During the mid-1970s, sylvatic fox rabies virus variant surpassed 82 
the canine variant (Yakobson et al., 1998). Since 1998 wildlife rabies has been controlled 83 
through the use of oral rabies vaccines (Yakobson et al., 2006). However, despite mandatory 84 
dog vaccination, canine rabies has re-emerged in northern Israel, resulting in rabies cases in 85 
unvaccinated dogs and other species (David et al., 2009; David, Bellaiche, and Yakobson, 86 
2010; David and Yakobson, 2011).  87 
Given continued rabies virus transmission in Israel, dogs must be tested to ensure 88 
adequate RNVA titres (≥0.5 IU/ml) for travel certification. This study used data obtained 89 
from routine pre-travel testing of dogs to explore factors associated with failure to achieve 90 
adequate RNVA titres for travel in vaccinated dogs. We consider how these findings may 91 
inform broader discussions about vaccination strategies for domestic pets. 92 
Materials and methods 93 
Data source 94 
Dogs travelling to certain countries outside of Israel are required to have an RVNA titre ≥0.5 95 
IU/ml (hereafter referred to as an adequate RVNA titre for travel). The National Rabies 96 
Laboratory at the Kimron Veterinary Institute, part of the Israeli Veterinary Services and 97 
Animal Health (IVSAH), has performed travel certification serology (hereafter referred to as 98 
a pre-travel titre) since 2004.The laboratory is accredited by the National Laboratory 99 
Accreditation Authority and annually meets the requirements of inter-laboratory testing 100 
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organized by the EU-designated Institute AFSSA-Nancy (France). Serum RVNA were 101 
measured using the rapid fluorescent focus inhibition test (RFFIT; Smith et al., 1973, 102 
modified by Zalan et al., 1979). 103 
Dog licensure is mandatory in Israel and requires identification by microchip, 104 
registration in a central database and having recorded vaccination against rabies during the 105 
last year. Annual re-vaccination is required to maintain validity. The IVSAH is responsible 106 
for management of the national computerized dog registration database, which includes each 107 
animal’s age, sex and vaccination history. 108 
Study design 109 
Data were extracted from the IVSAH national dog registration database held by including a 110 
study population of dogs presented for travel certification RVNA titres from 3rd January 111 
2010 to 19th May 2014. The following variables were extracted from the national registry for 112 
each dog as explanatory variables (i.e., putative risk factors): sex; age at most recent rabies 113 
vaccination prior to blood draw for the pre-travel titre (in months; hereafter “age at most 114 
recent vaccination”); number of rabies vaccinations prior to blood draw for the pre-travel titre 115 
(hereafter “number of previous vaccinations”), and time between the most recent rabies 116 
vaccination and blood draw for a pre-travel titre (in days; hereafter “gap between vaccination 117 
and titre”). These records were linked to the date and outcome of the pre-travel titre reported 118 
by the Kimron Veterinary Institute by microchip identification number. Microchip numbers 119 
were subsequently removed to protect owner privacy.  120 
We then performed a retrospective case-control analysis, where cases were defined as 121 
dogs presented for testing that did not achieve an adequate RVNA titre for travel, and 122 
controls were those presented for testing that did achieve an adequate RVNA titre for travel. 123 
Controls were randomly selected stratified by year with a 1:1 case-to-control ratio using the 124 
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random number function in Microsoft Excel (v. 2010, Microsoft Corporation, Washington, 125 
USA).  126 
Data analysis 127 
Associations among putative risk factors and between these factors and titre status (case or 128 
control) were assessed using a Spearman’s rho rank correlation for associations between two 129 
continuous variables, a t-test between continuous and binary variables, or the Χ2 or Fisher’s 130 
exact test between two binary variables. Strength of associations was expressed as an odds 131 
ratio (OR) with 95% confidence interval (CI; Taylor series, Dean, Sullivan and Soe, 2015). 132 
An odds ratio that is significantly greater than one indicates that the risk factor is associated 133 
with increased likelihood of failing to achieve an adequate RVNA titre for travel. Where 134 
significant associations between risk factors were detected, stratified analyses were 135 
performed to consider the effects of confounding on univariate results.  136 
Since the incremental impact of continuous factors may not necessarily be linear, risk 137 
factors were transformed into binary categories for some analyses. Categories were defined 138 
by visual examination of each variable’s distribution for natural breaks or based on pertinent 139 
biological information (e.g., 15 months is the age at which dogs would typically receive a 140 
second rabies vaccination). Continuous variables converted to binary categories were age at 141 
most recent vaccination (≤15 month old or >15 months old), number of previous vaccinations 142 
(only one vaccination or >1 vaccination received), and the gap between vaccination and titre 143 
(≤60 days or >60 days).  144 
Multivariate logistic regression modelling was then performed to provide adjusted 145 
ORs for each risk factor. Logistic regression with forwards and backwards stepwise model 146 
selection was performed, with the criteria for entry and exit of parameters being a significant 147 
change in the model deviance as judged by a p-value of ≤0.1. 148 
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First, a “base” model was constructed for model selection using all putative risk 149 
factors (sex, age at most recent vaccination, number of previous vaccinations, and the gap 150 
between vaccination and titre). Different variables were offered as starting variables in 151 
repeated runs to assure that the final model was not dependent on the order of factor entry 152 
and exit. This base model had no restrictions on variable entry or exit from the model. 153 
We then constructed additional multivariable logistic regression models to consider 154 
potential confounding between age at most recent vaccination and other putative risk factors 155 
before arriving at a final model. Due to concern that effects of age at most recent vaccination 156 
could be confounded by associations with other variables, a second model was constructed in 157 
which the age at most recent vaccination variable was forced to remain in all models through 158 
the model selection process (“age forced” model). Next, two age-stratified models were 159 
constructed by model selection, one using only the data for young animals (≤15 months at 160 
most recent vaccination; “young” model) and one using only the data for adult animals (>15 161 
months at most recent vaccination; “adult” model). Then, a final model was built guided by 162 
the findings of these exploratory models and including biologically relevant interaction terms.  163 
 This final logistic regression model produced OR estimates adjusted for complex 164 
associations among multiple factors and failure to achieve an adequate RVNA titre for travel 165 
that were then used to estimate the odds of failing to achieve an adequate RVNA titre for 166 
travel (i.e., scenario risk assessments), given specific combinations of factors (scenarios) for 167 
variables included in the model (e.g., for a young dog, having had only one vaccination 168 
within 60 days of the test). Odds was converted to probability (risk) of failing to achieve an 169 
adequate RVNA titre for travel using the equation: probability = odds/(1+odds). 170 
 Finally, to assess representativeness of findings for the broader registered dog 171 
population, a sample was extracted from Israel’s national dog registration database to serve as 172 
a snapshot of the overall registered dog population’s vaccination history. Demographic and 173 
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vaccine history of the registered dog population during August 2013 was qualitatively 174 
compared to the population of dogs presented for travel certification during 2013. 175 
All statistical tests and regression modelling were carried out using the statistical 176 
package Statistix version 10 (© 1985-2013 Analytical Software, Tallahassee, FL, USA). 177 
Results 178 
Sample description 179 
From 3rd January 2010 to 19th May 2014, 4,949 dogs presented for travel certification, 180 
evenly distributed across years (range of 1,000-1,200 dog/year). Of these, 395 (8.0%) did not 181 
have an adequate RVNA titre for travel but many of these did have detectable RVNA below 182 
0.5 IU/ml (for these, median titre=0.18 IU, range=0.02-0.48 IU). Forty nine of these 395 183 
cases were excluded due to incomplete records for one or more necessary variables. 184 
Therefore 346 cases and 346 controls (692 dogs total) were selected for analysis. 185 
Univariate and stratified analysis 186 
Approximately half of both cases (49%) and controls (47%) were male (Table 1a). A 187 
significantly larger portion of cases received only one vaccination prior to presentation for 188 
pre-travel titre (85% versus 35.3% of controls), had received the most recent vaccination at ≥ 189 
15 months old (62.4% versus 27.5% of controls), and had a gap of >60 days between 190 
vaccination and titre (80.3% versus 60.1% of controls; Table 1a). 191 
Mean gap between vaccination and titre did not differ significantly between cases 192 
(173 days) and controls (160 days; T-test: p-value=0.3896). However, despite similar means, 193 
the distribution of gap between vaccination and titre was different between cases and controls 194 
(Figure 1). Specifically, 40% of test dates for the controls fell within 60 days of the most 195 
recent vaccination compared to only 20% for the cases (Χ2 test: p-value<0.0001). 196 
 Assessment of associations among these putative risk factors revealed a notable 197 
potential confound between the number of previous vaccinations and the age at most recent 198 
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vaccination. Both variables differed significantly between cases and controls as both binary 199 
categories (Table 1a) and in the original continuous variable (Spearman rank coefficient 200 
=0.6854, p-value<0.0001; Table 2). The mean age at most recent vaccination for dogs having 201 
received only one previous vaccination was 15.5 months, compared with 53.3 months for 202 
dogs that had received more than one previous vaccination (T-test: p-value <0.0001; Table 203 
2).  204 
Given this association between age at most recent vaccination and number of previous 205 
vaccinations, two stratified analyses were performed. When stratified by the number of 206 
previous vaccinations, age at most recent vaccination was not significantly associated with 207 
not having an adequate RVNA titre for travel (i.e., being a case; Table 2b), yet when 208 
stratified by age at most recent vaccination, the number of previous vaccinations was 209 
significantly associated with the case outcome and with a similar OR for both age groups 210 
(Table 2c). 211 
Significant associations were not noted among other putative risk factors; for this 212 
reason, additional bivariate analyses were not performed.  213 
Logistic regression modelling 214 
The base logistic regression model retained two significant factors: having only one previous 215 
rabies vaccination and having a > 60 day gap between vaccination and titre (Table 3). When 216 
age at most recent vaccination was forced to remain in the model (age forced), age was not 217 
significant and the model was otherwise similar to the base model, indicating no significant 218 
direct influence of age. In the stratified models for either young or adult dogs, the ORs for 219 
number of previous vaccinations and gap between vaccination and titre differed from that in 220 
the base model (although with wider 95% CIs), suggesting that age may have some 221 
modifying effect on the influence on these factors (Table 3). Finally, when interaction terms 222 
(age at most recent vaccination x number of previous vaccinations, age at most recent 223 
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vaccination x gap between vaccination and titre, and number of previous vaccinations x gap 224 
between vaccination and titre) were included in the final model selection, the interaction 225 
between age at vaccination and gap between vaccination and titre was significant and both 226 
variables were retained in the final model (Table 4). 227 
Scenario risk estimation 228 
The highest estimated risk of failure to achieve an adequate RVNA titre for travel was for 229 
dogs tested > 60 days after receiving their first vaccination (81% for young dogs;73% for 230 
adults; Figure 2). In contrast, estimate risk of failure to achieve an adequate RVNA titre for 231 
travel was lowest for dogs that had received one or more booster vaccination and were tested 232 
within 60 days of receiving the most recent vaccination (8% in young dogs; 13% is adults; 233 
Figure 2). 234 
Evaluation of study representativeness 235 
The snapshot of 367,388 registered dogs in the national dog registration database 236 
during August 2013 was compared to dogs in the study population during 2013. The 237 
registered dog population sex ratio (50% male) was similar to that of travelling dogs (48%). 238 
The proportion of young animals (≤15 months) was less in the registered population (7%) 239 
than for dogs presented for pre-travel testing (24%). The difference in the proportion of dogs 240 
with only one vaccination was smaller: 29% of the registered dogs had only one rabies 241 
vaccination compared with 36% of the travelling dogs.  242 
Discussion 243 
Failure to achieve adequate RVNA titre for travel occurred in approximately 8% of the study 244 
population of dogs presenting for travel certification in Israel during January 2010-May 2014. 245 
However, many dogs failing to reach the threshold for travel certification (0.5 IU/ml) did 246 
have a detectable RVNA titre and may or may not have had sufficient protection against 247 
rabies virus if exposed.  248 
11 
 
Case-control analysis suggested higher odds of failure to achieve an adequate RVNA 249 
titre for travel (cases in this analysis) in primo vaccinates or dogs vaccinated >60 days prior 250 
to blood collection for titre.  Effects of age (measured in this study as the age at most recent 251 
vaccination) were confounded by correlation of this variable with the number of previous 252 
vaccinations received. This association is not unexpected, as young animals will more 253 
typically have only received a single documented vaccination when dogs are receiving rabies 254 
vaccination on the recommended schedule. Stratified analysis suggested that the number of 255 
previous vaccinations was the driving variable in the observed relationship, with fewer dogs 256 
having received more than one vaccination in cases compared to controls in both the young 257 
(≤15 mo) and older (>15 mo) groups. In contrast, age group proportions did not differ 258 
between cases and controls when stratified by the number of previous vaccinations, a finding 259 
supported during exploratory multivariate analysis by the negligible impacts of forcing 260 
retention of the age at most recent vaccination variable during model selection. 261 
The strongest explanatory variables in the final logistic model was the number of 262 
previous vaccinations, followed by the gap between vaccination and titre. In this model, age 263 
at most recent vaccination was not itself a significant effect but did significantly interact with 264 
the gap between vaccination and titre, with a higher odds of failure to achieve an adequate 265 
RVNA titre for travel in young animals with a >60 day gap. The estimated odds of failure to 266 
achieve an adequate RVNA titre for travel for dogs with only one previous rabies vaccination 267 
was approximately 3x higher than  those with more than one previous vaccination if tested 268 
within 60 days and was 5x higher if tested after 60 days. 269 
The sub-population of dogs presented for travel certification contained more young 270 
dogs and more dogs with only one previous rabies vaccination compared to the registered dog 271 
population in Israel. This suggests that the 8% of dogs that failed to achieve an adequate titre 272 
for travel in the study population may be an overestimate for the general dog population in 273 
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Israel. Of dogs in the study population that failed to achieve an adequate titre, 36% had 274 
received only one vaccination when blood was drawn for pre-travel titre, whereas 29% of the 275 
general population had only one rabies vaccination. 276 
These findings agree with previous work in assessing travel titre levels in dogs which 277 
generally find that age, time since vaccination, and in particular booster vaccination are 278 
critical factors for a reasonable assurance of protection against rabies during travel, as 279 
measured by adequacy of RVNA titre levels (Cliquet et al., 2003; Zanoni et al., 2010; 280 
Berdtsson et al., 2011; Klevar et al., 2015). While dogs with titre values below the 0.5 IU 281 
threshold accepted for travel could be protected, assurance of protection is less certain below 282 
this accepted titre value (Aubert, 1992). The practical implication of these results is that dogs 283 
should not be considered to have strong assurance of being protected from rabies virus 284 
infection until they have received at least two vaccinations. While risk of failing to achieve an 285 
adequate titre for travel certification is highest in young dogs, who under current vaccination 286 
schedules in many countries will not receive a rabies booster vaccination until over one year 287 
of age, our study suggests that the risk for adult primo vaccinates is also elevated. Rescue 288 
animals in particular may be a particularly high-risk group for failure to achieve sufficient 289 
antibodies for assurance of protection due not only to being primo vaccinates but other health 290 
issues that my reduce vaccine efficacy in these populations (Klevar et al., 2015). 291 
Dog rabies vaccination protocols are well established and largely agreed upon by 292 
public health advisory bodies and vaccine manufacturers (WHO, 1992; Brown et al., 2011; 293 
OIE, 2013). A single dose of rabies vaccine is generally sufficient to immunise, due to the 294 
potent glycoprotein G antigen included along with a powerful adjuvant (Petrovsky and 295 
Aguilar, 2004). Available canine rabies vaccines are licensed as providing either a one or 296 
three year duration of immunity (DOI) (Brown et al., 2011) and when required in regulations, 297 
the timing of subsequent doses is typically determined by this licensed DOI except for the 298 
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timing of the first booster dose. To ensure adequate population-level protection, a second 299 
dose at up to a year after the first dose is strongly recommended to improve titres in 300 
individuals with insufficient primary antibody response (Brown et al., 2011). Low antibody 301 
production on initial vaccination is of particular concern in puppies due to potential 302 
interference from maternally derived antibodies. 303 
In countries where dog vaccination is routine and obligatory, most puppies are born 304 
with protective levels of maternally derived antibodies that will gradually decline to a level 305 
that allows successful active immunization at between six and 12 weeks of age (Aghomo et 306 
al., 1990; Mitmoonpitak & Tepsumethanon, 1998). In the period of waning of maternal 307 
antibodies prior to development of active immunity young animals may not be protected 308 
(Mitmoonpitak & Tepsumethanon, 1998; Clark & Wilson, 1996). Maternally-derived 309 
antibody levels and rate of decline vary such that some puppies may respond poorly to 310 
vaccination up to 12 weeks of age or older. 311 
A common protocol for rabies vaccination specifies initial vaccination of puppies at 312 
eight to twelve weeks of age then a second vaccination one year later, followed by booster 313 
vaccinations at one or three year intervals, depending on the licensed DOI of the vaccine used 314 
and country regulations (Brown et al., 2011). In contrast, vaccination programs in canine 315 
rabies endemic areas assume that many puppies will not have maternal antibodies to interfere 316 
with primary vaccination. However, poor responders to primo vaccination will occur in all 317 
dog populations, resulting in a low but real risk for rabies in these animals if exposed to 318 
rabies virus. 319 
The World Small Animal Veterinary Association recently recommended that a second 320 
dose of vaccine should be given two to four weeks after the first dose in high-risk regions, if 321 
permitted by law (Day et al., 2010). Similarly, the European Food Safety Authority has 322 
suggested that more proximate booster vaccination (within 4-6 weeks) would reduce risk of 323 
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rabies translocation by insufficiently protected primo vaccinates even more effectively than 324 
monitoring for a serologic threshold prior to travel (ESFA, 2006). However, compliance with 325 
a shortened booster schedule for rabies vaccination could be poor if recommendations are not 326 
aligned with other vaccination schedules. Further study would be beneficial to determine the 327 
ideal timing of the first booster vaccination to reduce the risk period during which titre levels 328 
may have fallen below the desired protection threshold in low-responders at primo 329 
vaccination. After receiving the first booster, providing additional booster vaccinations on the 330 
schedule determined by the vaccine’s licensed DOI and local regulation is important to 331 
ensure sustained immunity. However, in order to maximise rabies protection in the general 332 
dog population, the first priority should be to ensure as many dogs as possible have received 333 
at least two vaccinations. 334 
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travel titre. 440 
Figure 2: Estimated risk of failure to have an adequate RVNA titre for different scenarios, 441 
estimated using the logistic regression model. “Gap” refers to the time passed between the 442 
most recent rabies vaccination and presentation for pre-travel titre. 443 
19 
 
Tables 444 
Table 1. Preliminary analysis of variables associated with adequacy of rabies neutralizing antibody titre in dogs presenting for travel 445 
certification, Israel – Jan. 2010 to May 2014 446 
(a) INITIAL UNIVARIATE ANALYSES     Odds ratio (95% confidence interval) 
&Yates' Corrected Chi2 p-value (2 tail)   Variable (exposure factor)   n %'exposed' 
 
Gender (male) 
Cases 276‡ 49.3% 
1.12 (0.81 to 1.53) p=0.546  Controls 344‡ 46.5% 
 
Number of previous vaccinations (Only one) 
Cases 346 85.0% 
10.38 (7.18 to 15.00) p<0.0001$  Controls 346 35.3% 
 Age at  most recent vaccination (≤15 months) 
Cases 346 62.4% 
4.39 (3.18 to 6.05) p<0.0001$ 
 Controls 346 27.5% 
 
Gap between vaccination and titre (>60 days) 
Cases 346 80.3% 
2.71 (1.93 to 3.82) p<0.0001$ 
 Controls 346 60.1% 
(b) STRATIFIED ANALYSES: effect of age at most recent vaccination for dogs with a different number of previous vaccinations. 
 Variable (exposure factor)  n %'exposed'  
STRATUM:  
only one vaccination 
Age at most recent vaccination ≤15 months 
Cases 294 72.4% 
1.14 (0.72 to 1.82) p=0.6509 
Controls 122 69.7% 
STRATUM:  
>1 vaccination 
Age at most recent vaccination ≤15 months 
Cases 52 5.8% 
1.31 (0.35 to 4.94) p=0.9138* 
Controls 224 4.5% 
(c) STRATIFIED ANALYSES: effect of number of previous vaccinations for dogs most recently vaccinated at different ages. 
 Variable (exposure factor)  n %'exposed'  
STRATUM:  
vaccination at ≤15 months 
Only one vaccination received 
Cases 216 98.6% 
8.35 (2.24 to 31.09) p=0.0012*, $ 
Controls 95 89.5% 
STRATUM:  
vaccination at >15 months 
Only one vaccination received 
Cases 130 62.3% 
9.56 (5.81 to 15.72) p<0.0001$ 
Controls 251 14.7% 
‡some cases did not have gender recorded 447 
*Fisher exact p-value used here because conditions not met to use Χ2 448 
$Significant at α<0.05. 449 
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Table 2: Comparison of mean age of cases and controls for the whole dataset and, separately, 450 
for dogs with only one and dogs with more than one previous rabies vaccination. 451 
Number of previous 
vaccinations 
Group 
Mean age* in 
months (±SE) 
p-value** 
≥1 vaccinations 
(all dogs in study) 
Cases (n=346) 20.5 ±1.6 mo 
<0.0001$ 
Controls (n=346) 40.7 ±2.0 mo 
Cases & controls (n=692) 30.6 ±1.3 mo  
Only 1 vaccination 
(60% of all dogs in study) 
Cases (n=294) 16.0 ±1.4 mo 
0.4399 
Controls (n=122) 14.2 ±1.8 mo 
Cases & controls (n=416) 15.5 ±1.1 mo  
>1 vaccination 
(40% of all dog in study) 
Cases (n=52) 45.8 ±5.5 mo 
0.1273 
Controls (n=224) 55.1 ±2.4 mo 
Cases & controls (n=276) 53.2 ±2.2 mo  
* Age=age at most recent vaccination in months 452 
** P-value represents a two-tailed t-test for cases versus controls. 453 
$ Significant at α<0.05. 454 
 455 
Table 3: Parameter estimates of exploratory multivariable logistic regression models for 456 
likelihood of failing to achieve an adequate RVNA titre in dogs presented for travel 457 
certification 458 
Variable Model Coefficient (SE) Adj. OR (95% c.i.) p-value 
Intercept    
 ‘Base’ -2.33245 (0.22778) - - <0.0001* 
 Age forced -2.33232 (0.22759) - - <0.0001* 
 Young (≤15 mo old) -2.14831 (0.72174) - - 0.0029* 
 Adult (>15 mo old) -1.95515 (0.26658) - - <0.0001* 
Age at most recent vaccination (exposure: ≤15 mo old)*    
 ‘Base’ - - - - - 
 Age forced 0.07971 (0.23289) 1.08 (0.69-1.71) 0.7322 
 Young (≤15 mo old) - - - - - 
 Adult (>15 mo old) - - - - - 
Number of previous vaccinations (exposure: only one vaccination)    
 ‘Base’ 2.41769 (0.19518) 11.22 (7.65-16.45) <0.0001* 
 Age forced 2.36395 (0.24984) 10.68 (6.52-17.35) <0.0001* 
 Young (≤15 mo old) 1.92167 (0.70891) 6.83 (1.70-27.42) 0.0067* 
 Adult (>15 mo old) 2.31752 (0.25989) 10.15 (6.1-16.89) <0.0001* 
Gap between vaccination and titre (exposure: gap >60 d)    
 ‘Base’ 1.16636 (0.2019) 3.21 (2.16-4.77) <0.0001* 
 Age forced 1.16217 (0.20215) 3.20 (2.15-4.75) <0.0001* 
 Young (≤15 mo old) 1.65068 (0.28236) 5.21 (3.00-9.06) <0.0001* 
 Adult (>15 mo old) 0.6634 (0.27817) 1.94 (1.13-3.35) 0.0171* 
*Coefficients are deviation of “exposure” level listed from the alternative referent level for each 459 
binomial variable (≤15 mo old:>15 mo old; only one vaccination: >1 vaccination; gap ≤60 d: gap 460 
>60 d) 461 
** Significant at α<0.05. 462 
 463 
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Table 4: Parameter estimates of final multivariable logistic regression model for likelihood of 464 
failing to achieve an adequate RVNA titre in dogs presented for travel certification 465 
Variable and level Coefficient (SE) Adjusted OR (95% CI) p-value 
Intercept -1.93271 (0.26137) - <0.0001** 
Age at most recent vaccination (“Age”)    
Young (≤15 months) -0.55717 (0.34353) 0.57 (0.29-1.12) 0.1048 
Adult (>15 months) Ref. 1.0  
Number of previous vaccinations    
Only one vaccination 2.2738 (0.24489) 9.72 (6.01-15.7) <0.0001** 
>1 vaccination Ref. 1.0  
Gap between vaccination and titre    
Long gap (>60 days) 0.65557 (0.2762) 1.93 (1.12-3.31) 0.0176** 
Short gap (≤60 days) Ref. 1.0  
Interaction: Age x Gap 0.99766 (0.39562) 2.71 (1.25-5.89) 0.0117** 
*Overall model: Deviance =729.12; p-value = 0.1289; Degrees of freedom=687. As deviance 466 
reduces the better the correspondence between the observed and fitted values, a non-467 
significant p-value indicates no gross deficiencies with the overall model fit. 468 
** Significant at α<0.05. 469 
 470 
